Bicara Therapeutics (BCAX) Shares Outstanding (2023 - 2026)
Bicara Therapeutics (BCAX) posted quarterly Shares Outstanding (Entity) of $65.5 million for Q1 2026, up 20.21% year-over-year from $54.5 million in Q1 2025, and down 99.88% quarter-over-quarter from $54.7 billion in Q4 2025.
Bicara Therapeutics (BCAX) Shares Outstanding (2023 - 2026) Analysis & Trends
Bicara Therapeutics' Shares Outstanding (Entity) history runs 4 years deep, the most recent figure standing at $65.5 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 20.21% year-over-year to $65.5 million; the TTM figure through Mar 2026 stood at $65.5 million (up 20.21% YoY), while the FY2025 annual figure was $54.7 billion, up 225.35% from the prior year.
- Shares Outstanding (Entity) for Q1 2026 stood at $65.5 million, down from $54.7 billion in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $54.7 billion in Q4 2025, with the low at $579975.0 in Q3 2023.
- The 4-year median for Shares Outstanding (Entity) is $54.6 million (2025), against an average of $6.6 billion.
- The sharpest annual moves came in 2025 and 2026: Shares Outstanding (Entity) soared 8415.02% in 2025, then grew 20.21% in 2026.
- Bicara Therapeutics' Shares Outstanding (Entity) stood at $580.1 million in 2023, then surged by 2796.96% to $16.8 billion in 2024, then jumped by 225.35% to $54.7 billion in 2025, then slumped by 99.88% to $65.5 million in 2026.
- Business Quant data shows BCAX's Shares Outstanding (Entity) at $65.5 million in Q1 2026, $54.7 billion in Q4 2025, and $54.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Bicara Therapeutics | 1.60 Bn | 1.60 Bn | - | 67.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 67.93 Mn |
| Mar 31, 2026 | 60.72 Mn |
| Dec 31, 2025 | 54.68 Bn |
| Sep 30, 2025 | 54.56 Mn |
| Jun 30, 2025 | 54.54 Mn |
| Mar 31, 2025 | 54.46 Mn |
| Dec 31, 2024 | 16.81 Bn |
| Sep 30, 2024 | 10.90 Mn |
| Jun 30, 2024 | 896,744.00 |
| Mar 31, 2024 | 660,288.00 |
| Dec 31, 2023 | 580.11 Mn |
| Sep 30, 2023 | 597,586.00 |